Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Polynovo ( (AU:PNV) ) has provided an update.
PolyNovo has released a recording of its May 2025 Investor Update Webcast for shareholders and interested parties who missed the live event. This announcement underscores PolyNovo’s commitment to transparency and stakeholder engagement, potentially strengthening its market position and investor relations.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo is a disruptive medical technology company based in Melbourne, Australia, specializing in products that simplify the management of acute complex wounds. The company has treated over 70,000 patients across 46 countries and is focused on growth through new products, indications, and market expansion. Its flagship product, NovoSorb BTM, is a dermal scaffold used for dermis regeneration after surgery, trauma, or burns, known for its biocompatibility and customizable bio-resorption properties.
Average Trading Volume: 3,155,378
Technical Sentiment Signal: Sell
Current Market Cap: A$1.15B
For a thorough assessment of PNV stock, go to TipRanks’ Stock Analysis page.